Table 1 Association between preanalytic variables and risk for MPS failure in fixed tissue specimens.

From: Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice

Preanalytic variable

MPS successa (n = 278)

No. (%)b

MPS failurea (n = 40)

No. (%)b

Est. odds ratio (95% CI)

p valuec

Collecting institution

 Intramurald

175 (95)

9 (5)

1.0

 

 Extramural

103 (77)

31 (23)

5.25 (2.44–12.3)

<0.0001*

Tumor, %e

 ≥50%d

223 (90)

25 (10)

1.0

 

 <50%

55 (79)

15 (21)

2.22 (1.01–4.75)

0.0425*

Specimen source

 Extranodald

138 (90)

16 (10)

1.0

 

 Lymph node

132 (87)

20 (13)

1.19 (0.566–2.52)

0.649 ns

 Bone marrowf

8 (67)

4 (33)

1.22 (0.261–5.13)

0.786 ns

Specimen type

 Excisional biopsyd

186 (89)

22 (11)

1.0

 

 Core biopsy or aspirate clotg

92 (84)

18 (16)

1.62 (0.736–3.50)

0.223 ns

  1. aMPS success is defined as an MPS result of DAV, VUS only, or NV, while MPS failure is defined as being either quantitative failure (QTF) due to insufficient DNA or qualitative failure (QLF) due to inadequate DNA quality. Fixed MLN cases with calculable tumor percent were analyzed (n = 318, see Fig. 1). Excluded from this analysis are “Fresh” cases (n = 167) due to lack of MPS failure in this preanalytic category and thus perfect separation from the “fixed” category.
  2. bThe percentage reported is the percent of the preanalytical variable within each MPS result category.
  3. cp values with summary, reported as not significant (ns) ≥0.05, *<0.05.
  4. dReference category, see “Materials and methods” for further details.
  5. eTumor percent as determined by the pathologist or calculated, see “Materials and methods” for further details.
  6. fBone marrow specimens in this analysis consisted of aspirate clots as there was no MPS failure in fresh aspirates specimens; MPS was attempted on a single decalcified bone marrow core biopsy as no alternate material was available which resulted in a QTF as expected for this unacceptable specimen type.
  7. gTo prevent linearity between specimen source and type, aspirate clot and tissue core biopsies were combined for this analysis as a similar yield of material is expected for these specimens. “Aspirate clot” includes bone marrow aspirate clots (11) and FNA cell block (1), while “core biopsy” refers to all other non-excisional lymph node or other tissue biopsy.
Back to article page